Approval

FDA Approves Infilbray

The FDA approved Sanofi's oral Infilbray for neurological symptoms of type 3 Gaucher disease in adults and children weighing at least 15 kg. In the 43-patient phase 3 LEAP2MONO study, the combined neurological endpoint favored Infilbray over enzyme replacement therapy at week 52 (P=0.0179). The drug can cross the blood-brain barrier; its application for type 3 Gaucher disease remains under review by the European Medicines Agency.

Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call